WO2006001654A1 - Composition contenant de l'extrait de ginseng comprenant des derives de saponine isoles du radix ginseng et ginseng utilise pour empecher et traiter les maladies induites par les griffures - Google Patents

Composition contenant de l'extrait de ginseng comprenant des derives de saponine isoles du radix ginseng et ginseng utilise pour empecher et traiter les maladies induites par les griffures Download PDF

Info

Publication number
WO2006001654A1
WO2006001654A1 PCT/KR2005/001970 KR2005001970W WO2006001654A1 WO 2006001654 A1 WO2006001654 A1 WO 2006001654A1 KR 2005001970 W KR2005001970 W KR 2005001970W WO 2006001654 A1 WO2006001654 A1 WO 2006001654A1
Authority
WO
WIPO (PCT)
Prior art keywords
ginseng
ginsenoside
ginseng extract
ferment
scratching
Prior art date
Application number
PCT/KR2005/001970
Other languages
English (en)
Inventor
Dong-Hyun Kim
Sang Wook Kim
Myung Joo Han
Original Assignee
Hongrim Trading Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hongrim Trading Co., Ltd. filed Critical Hongrim Trading Co., Ltd.
Publication of WO2006001654A1 publication Critical patent/WO2006001654A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)

Definitions

  • the present invention relates to a composition for preventing or treating scratching diseases (pruritus) containing at least one ginseng extract selected from the group consisting of ginseng or red ginseng extract, its lactic-acid bacteria ferment and its intestinal bacteria ferment, or ginseng saponin derivatives isolated therefrom as effective components .
  • ginseng extract selected from the group consisting of ginseng or red ginseng extract, its lactic-acid bacteria ferment and its intestinal bacteria ferment, or ginseng saponin derivatives isolated therefrom as effective components .
  • Scratching diseases include paroxysmal scratching diseases such as lichen simplex chronicus, atopic dermatitis, dermatitis herpetiformis, which are very serious, chronic and recurring scratching diseases; men's scrotum scratching diseases and vulvar scratching diseases due to the mental-related facts as induced by candidiasis, trichomonas vaginitis, contact dermatitis caused by contact with pad, contraceptive, vagina cleansing lotion and condom, urinary incontinence, diabetes mellitus, sclerosing atrophic chronicus; and scratching diseases that are related to itchy skin diseases induced by dermatitis herpetiformis, insect bites, scab, atopic dermatitis, contact dermatitis, psoriasis, nummular eczema, chronic simplex chronicus, erythema prurigo, systemic dermatitis.
  • paroxysmal scratching diseases such as lichen simplex chronicus, a
  • the present inventors have been conducting numerous researches in order to develop natural substances that can substitute the chemical synthetic medicaments for treating scratching diseases which have serious side effects.
  • the present inventors have found that at least one ginseng extract selected from the group consisting of ginseng or red ginseng extract, its lactic- acid bacteria ferment and its intestinal bacteria ferment, or ginseng saponin derivatives isolated therefrom has excellent effects for preventing and treating scratching diseases and that as natural substances, they do not produce side effects to the human body at all.
  • the object of the present invention is to provide a new composition for preventing or treating scratching diseases .
  • the present invention provides a composition for preventing or treating scratching diseases containing at least one ginseng extract selected from the group consisting of ginseng or red ginseng extract, its lactic-acid bacteria ferment and its intestinal bacteria ferment, or ginseng saponin derivatives isolated therefrom as effective components.
  • the present invention provides a method of preventing or treating scratching diseases comprising administration of at least one ginseng extract selected from the group consisting of ginseng or red ginseng extract, its lactic-acid bacteria ferment and its intestinal bacteria ferment, or ginseng saponin derivatives isolated therefrom to patients in need.
  • ginseng extract selected from the group consisting of ginseng or red ginseng extract, its lactic-acid bacteria ferment and its intestinal bacteria ferment, or ginseng saponin derivatives isolated therefrom to patients in need.
  • the present invention provides a use of at least one ginseng extract selected from the group consisting of ginseng or red ginseng extract, its lactic- acid bacteria ferment and its intestinal bacteria ferment, or ginseng saponin derivatives isolated therefrom for manufacturing of medicament for preventing or treating scratching diseases .
  • the present invention provides, as a ginseng saponin derivative isolated from said ginseng extract, at least one ginseng saponin derivatives selected from the group consisting of panaxytriol, panaxydol, panaxynol, ginsenoside Rc, ginsenoside RbI, Rb2, ginsenoside Rg3, compound K, ginsenoside Rh2, 20 (R) - ginsenoside Rh2, 20 (R) -protopanaxadiol, 20 (S)- protopanaxadiol, ginsenoside RhI, and 20 (S)- protopanaxatriol, desirably, a composition having in particular compound K(20-O-J3 -glucopyranosyl-20 (S) - Protopanaxadiol) , ginsenoside Rg3 and ginsenoside Rh2 as effective components, for preventing or treating scratching diseases.
  • a composition having in particular compound K(20
  • a composition of the present invention for preventing or treating scratching diseases comprises 0.02-90% by weight of said ginseng extract and ginseng saponin derivatives isolated therefrom with respect to the total weight of the composition.
  • ginseng extract includes extracts from ginseng or red ginseng extract and can be used as a generic term for products obtained by fermenting said extracts from ginseng or red ginseng by lactic-acid or intestinal bacteria.
  • a composition for preventing or treating scratching diseases according to the present invention is characterized in that it comprises a ginseng extract in its generic meaning.
  • ginseng saponin derivatives mean pharmacological components included in the ginseng extract. It not only comprises saponin already known in the pertinent art, but also unknown ginseng saponin derivatives included in ginseng extracts that could provide pharmacological components.
  • Ginseng is perennial plants belonging to Panax species of the Araliaceae, and approximately 11 species of ginseng are known so far. Typical species are; (1) Korea Insam ⁇ Panax ginseng CA. Meyer) grows in the Far Eastern Asia region (at a latitude of 33-48°N: Korea, North Manchuria, part of Russia) and its pharmacological effects are excellent; (2) U.S. ginseng (Panax quinquefolium L.) grows and is cultivated in the U.S. and Canada; (3) Panax notoginseng F.H.Chen grows and is cultivated from the southeastern Yunnan to the southeastern Guangxi Zhuangzu in China; and (4) Panax japonicus CA. Meyer grows in Japan, Southernwestern parts of China, and Nepal (Hwa Han Yak Baek Kwa Do Ram, Volume 1 at page 1-8, Nambatsunehiki, Hoiku Corp. , 1980) .
  • ginseng it can be classified into fresh ginseng (not dried after being picked up from the field) ; white ginseng (a fresh ginseng dried at a room temperature) ; and red ginseng (a fresh or white ginseng heated at 98-100) .
  • ginseng is proven to have the effects of strengthening a non-specific resistance of the body against stress, acid-oxidant function, treatment for hypertension, reinforcing the function of insulin, lowering a blood glucose level in rats with diabetes induced by alloxan RNA synthesis of white rat's liver, protein synthesis, stimulating sugar and lipid metabolism, and preventing cancer.
  • a herb medicine it has been used to treat various kinds of diseases such as psychiatric diseases, nervous system diseases and diabetes.
  • Saponin the major component of ginseng, has proven to have effects such as developing stamina and health, calming down, hematosis and antihypertensive effects (Nambatsunehiki et al. , Hwa Han Yak Baek Kwa Do Ram, 1, pp 1-8, 1980) .
  • the types of Efficacy ginsenoside The central nerve system suppression function and mental stability; feeding center suppression; suppression of aggressive behavior; alleviating pain; anti-convulsion; antianxiety; adrenocorticotropic hormone and corticosteroid secretion promotion; cholesterol biosynthesis promotion; memory improvement; decrease in high cholesterol, Ginsenoside- neutral fat and free fatty acid; nerve cell RbI survival promotion; liver protection; myeloid cell's DNA, RNA, protein and lipid synthesis promotion; acethylcholine emission promotion; vasodilution,- platelet agglutination inhibition; lipid peroxidation inhibition; cholesterol metabolism promotion; anti-inflammation; phagocytic function activation; kidney glomerular hypertrophy suppression Inhibition of Cancer cell breeding; promotion of inducement of cancer cell redifferentiation; inhibition of cancer Ginsenoside- cell invasion; inhibition of tumor Rh2 breeding; supporting anti-cancer medicine with its anti-cancer activity; anti-allergy effect; anti-inflammation effect
  • saponins such as compound K (20-0- ⁇ -
  • Rh2 and ⁇ 20-ginsenoside-Rh2, which are included in
  • ginseng such as anti-cancer
  • saponin components such as compound K (20- 0- ⁇ - glucopyranosyl-20 (S) - Protopanaxadiol) , ginsenoside- RhI and Rh2, and ⁇ 20-ginsenoside-Rh2, which are included in a ginseng in a very little amount.
  • the following components are effective in treating and preventing scratching diseases (itch; pruritus) : at least one ginseng extract selected from the group consisting of ginseng or red ginseng extract, its lactic-acid bacteria ferment and its intestinal bacteria ferment, or ginseng saponin derivatives isolated therefrom such as compound K, ginsenoside Rf, ginsenoside Rg3 and ginsenoside Rh2.
  • ginseng extracts from red ginseng produced according to the prior art contain a significant amount of ginsenoside Rg3, other saponin components such as compound K and ginsenoside Rh2 are not increased significantly.
  • the present inventors have found that if ginseng or red ginseng extracts are fermented by lactic-acid bacteria, compound K is increased significantly; however, in the case of ginseng lactic-acid bacteria ferment extracts, ginsenoside Rh2 is not increased significantly, but ginsenoside Rh2 is shown to be increased significantly only in red ginseng lactic- acid or intestinal bacterial ferment extracts.
  • Red ginseng was obtained by steaming the washed ginseng obtained in process (1) at 98-100 0 C for 1 to 10 hours, preferably for 2 to 5 hours with a commercially available red ginseng maker and then drying it at 60 0 C for 5 hours with a common drying machine.
  • Other necessary conditions and supplementary matters with regard to the process for preparing red ginseng are widely known in the pertinent art, and red ginseng which can be used for the process for preparing red ginseng according to the present invention can be prepared by the known method.
  • Saponin components were extracted from ginseng or red ginseng by extracting for 3 hours from and concentrating dried white ginsengs including fresh ginsengs and red ginsengs, using water or alcohol or a mixture of water and alcohol (preferably 70% of alcohol) , are to fifty times as much (weight/volume) , for 1 hour to two days, preferably for three hours at a temperature of 20 to 80 ° C, preferably from 50 to 60 °C .
  • Ginsengs applicable to this process include ginsengs, processed ginseng products and by-products, preferably fresh ginsengs, red ginsengs, white ginsengs, fine roots of ginseng, ginseng leaves, ginseng extracts and powdered ginseng. Ginseng extracts of these kinds can be optionally used in the below-mentioned bioconversion process.
  • Biologically fermented ginseng ferments were obtained by adding lactic-acid bacteria or intestinal bacteria to water extracts of fresh ginsengs, white ginsengs and red ginsengs, or concentrated water suspension of 70% alcohol extracts, and then culturing them at a temperature of 20 to 50 ° C, preferably 25 to 40 ° C for six hours to five days, preferably 24 hours to 48 hours.
  • fermenting time and fermenting temperature can be adequately chosen depending on the strain used and for extracting efficiency.
  • the ginseng ferment extracts obtained in the above process (4) can be used either as they are or are lyophilized for the present process. Or, they can be used after they are extracted with water or alcohol and the supernatant is concentrated or dried. This concentrating or lyophilization method has been widely known in the pertinent art.
  • the process of preparing red ginsengs converts ginsenoside-Rbl, ginsenoside-Rb2, ginsenoside-RC, etc., included in ginsengs to ginsenoside-Rg3, and the bioconversion process through lactic-acid bacteria or intestinal bacteria can convert thus obtained ginsenoside-Rg3 to the final metabolic product ginsenocide Rh2.
  • Direct bioconversion of white ginseng and fresh ginseng can convert ginsenoside-Rbl, ginsenoside-Rb2, ginsenoside-Rc to compound K only.
  • any lactic acid bacteria preferably a Bifidobacterium genus, more preferably one selected from Bifidobacterium infantis, B.bifidum, Lactobacillus lactis, Clostridium butyricum, Bifidobacterium H-I (KCCM 10493) , Bifidobacterium KK-I (KCCM 10364) , Bifidobacterium KK-2 (KCCM 10365), one of the selected from Bifidobacterium KK-Il (Kyung Hee University, College of Medicine, Professor Kim Dong-hyun) or their mixed strains.
  • a Bifidobacterium genus more preferably one selected from Bifidobacterium infantis, B.bifidum, Lactobacillus lactis, Clostridium butyricum, Bifidobacterium H-I (KCCM 10493) , Bifidobacterium KK-I (KCCM 10364) , Bif
  • any intestinal bacteria can be used, preferably intestinal bacteria of genus Bacteriodes, genus Fusobacterium, genus Eubacterium, more preferably Bacterioides JY-6 (Kyung Hee University, College of Medicine, Professor Kim Dong-Hyun, Biol. Pharm. Bull., 23, ppl481-1485,2000) , Fusobacterium K-60 (Kyung Hee University, College of Medicine, Professor Kim Dong-hyun, Biol. Pharm. Bull., 23, ppl481 ⁇ 1485,2000) , Eubacterium L-8 (Kyung Hee University, College of Medicine, Professor Kim Dong-hyun, Biol. Pharm. Bull., 23, ppl481-1485, 2000)
  • the above process (5) is optional while processes (3) and (4) are successive, essential processes if processes (1) and (2) are carried out; in process (4) red ginseng extract and strain can be mixed and prepared in a capsule so that they can be reacted in the human intestines without the process of cultivating them; and processes (3) and (4) can be carried out right after process (1) without going through process (2) where a red ginseng is prepared, and all of these processes can be optionally adopted according to the type of a final product.
  • the ratio of (ginsenoside Rh2+compound K) / (ginsenoside Rg3+Rc+Rd+Rbl+Rb2) of the ginseng extract of the present invention obtained after going through processes (1) to (4) including the red ginseng producing process, can be over 0.1.
  • the ratio of (compound K+ginsenoside Rd) / (ginsenoside Rc+Rd+Rbl+Rb2) of the ginseng extract of the present invention obtained after going through processes (1) , (3) and (4) , skipping the red ginseng preparation process (process (2)), can be over 0.1.
  • composition according to the present invention for preventing or treating scratching diseases containing at least one ginseng extract selected from the group consisting of ginseng or red ginseng extract, its lactic- acid bacteria ferment and its intestinal bacteria ferment, or ginseng saponin derivatives isolated therefrom as effective components can be produced in various commercial types of ginseng products by adding an optional substance or carrying out another optional process, as long as it does not negatively affect the effects of preventing and treating scratching diseases.
  • Types of ginseng products include, but are not limited to, for example, ginseng dried powder, extracts, ampoules, teas and tablets.
  • compositions containing extracts or compounds of the present invention can be prepared as a pharmaceutical preparation further including an adequate carrier, an excipient or a diluent according to commonly known methods.
  • Carriers, excipients or diluents that can be added to the extracts of the present invention or compositions comprising saponin derivatives included therein as effective components are lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium cilicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, talc, magnesium stearate and minerals.
  • extracts of the present invention or compositions comprising saponin derivatives included therein as effective components can be provided in oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, or be used as external applications, as suppositories, and as sterile water for injection or as cosmetics such as a soap, according to its ordinary method in the pertinent field.
  • the dosage of extracts of the present invention or saponin derivatives contained therein can differ according to the patient's age, sex and weight, but 0.1 to 100 mg/kg can be administered once or several times a day. Also, dosages of extracts and their compositions can be adjusted according to the route of administration, seriousness of the diseases, sex, weight and age. Accordingly, the above dosages do not, in any way, restrict the scope of the present invention.
  • the extracts of the present invention or compositions comprising saponin derivates included therein can be used in various types as discussed above in pharmaceuticals, foods, beverages and cosmetics for preventing and treating scratching diseases (pruritus) .
  • Foods to which extracts of the present invention or compositions including saponin derivates therein can be added are, for example, various foods, beverages, gums, teas, vitamin complexes, health supplement foods, and soap.
  • the extracts and compounds of the present invention by themselves are pharmaceuticals that can be used for preventing purposes for a long time without concerns about negative effects, because they do not have any toxins or side effects.
  • the extracts of the present invention or saponin derivatives included therein can be also added to food, beverages or cosmetics for preventing or treating scratching diseases .
  • the amount of extracts of the present invention or saponin derivates included therein can be 0.01 to 15 by weight % with respect to the total weight of the health supplement food or cosmetics, 0.02 ⁇ 20g/l00 ⁇ rv ⁇ for beverages, preferably 0.1 ⁇ lg (dry weight)
  • Health supplement foods or beverage compositions according to the present invention can optionally further include various flavoring agents or natural carbohydrate in a directed ratio.
  • natural carbohydrates include standard sugars such as monosaccharide (for example, glucose, fructose, etc.) ; disaccharide (for example, maltose, sucrose, etc.); and polysaccharide (for example, dextrin, cyclodextrin) ; and sugar alcohol (for example, xylitol, sorbitol and erythritol) .
  • natural flavoring agents thaumatin, stevia extracts, such as rebaudioside A, glycyrrhizin, etc.
  • synthetic flavoring agents sacharin, aspartame
  • the ratio of said carbohydrate is 0.1 ⁇ 20g per 100 n ⁇ (ioo g) of the composition of the present invention, preferably 0.5 ⁇ 5 g (dried weight) .
  • composition according to the present invention can further include various nutrients, vitamins, minerals (electrolyte) , synthetic and natural flavoring agents, coloring agents, improving agent in case of cheese and chocolate, pectic acid and its salt, alginic acid and its salt, organic acid, protective colloidal thickener, pH controlling agent, stabilizer, preservative, glycerin, alcohol, carbonating agent for carbonated beverages.
  • the compositions of the present inventions can further comprise fruit pulps for manufacturing natural fruit juices, fruit juice drinks and vegetable drinks, and these components can be used independently or in combination. The ratio of these additives are not restricted, but usually range from about 0 to 20 by weight% per 100 by weight% of the present composition.
  • composition of the present invention on scratching diseases can be confirmed in an in vivo experiment method to demonstrate the effect of azelastines (commercially available medical supplies) in inhibiting scratching disease by using animal models, wherein scratching disease is induced by compound 48/80, histamine, substance P, etc. of which the test methods are already established.
  • azelastines commercially available medical supplies
  • the above said method is carried out by intravenously injecting compound 48/80, histamine, substance P into the back of a mouse, etc., and then measuring its behavior (scratching, licking, etc.) made in response to itch.
  • a test sample can be intraperitonealIy administered 1 hour before or orally administered 3 hours before, and its inhibitory effect against the behavior made in response to itch can be measured.
  • red dry ginseng was extracted with 70% of alcohol to obtain red ginseng extracts.
  • Obtained red ginseng extracts was concentrated, suspended in water, extracted with BuOH and concentrated to obtain red ginseng extracts.
  • Example 5 Preparation of red ginseng intestinal ferment extracts lkg of 5-year-old fresh ginseng bought at Kumsan Ginseng Market was cleansed in water and then in water containing 0.1 % of acetic acid, steamed at 98-100°C for 4 hours, and dried at 60 ° C for 5 hours. Thus obtained dried red ginseng was extracted with 70% of alcohol to obtain red ginseng extracts.
  • This red ginseng extracts were suspended in sterile distilled water to get 0.5% of suspension to which was added an intestinal bacteria aggregate (1Og by- wet weight of a fungus body obtained by suspending fresh excrements of human in tryptic soy broth) , cultivated for 24 hours at 37 ° C in total 72 hours, extracted with BuOH and concentrated to obtain 4g of intestinal bacteria ferments of red ginseng.
  • ginsenoside Rg3 content in red ginseng was significantly- increased in comparison with that of white ginseng, and in the case of said ginseng being fermented with lactic acid bacteria or intestinal bacteria, Compound K content was increased. Further, in the case of red ginseng, the content of ginsenoside Rh2 (metabolized ginsenoside Rg3) was significantly increased.
  • Scratching behavior experiment was conducted in accordance with the Sugimoto method (Eur. J. Pharmacol., 351, 1-5, 1998) .
  • a group of five (5) rats consisting of BALB/c rats for an experimental animal model (Compound 48/80, Serotonin and Substance P) and ICR rats (an experimental animal model for histamine-induced itch) was left in a box (24x22x24cm) for observation for ten minutes .
  • the hair on the rear neck was removed, and by using 29-gauge needle, itch-inducing agent (50 ⁇ g of Compound 48/80, Sigma Chemical Corp., USA), 100 ⁇ g of histamine (Sigma, USA), 300 ⁇ g of serotonin (Sigma Chemical Corp., USA) or 100 ⁇ g of Substance P (Sigma Chemical Corp. , USA) were injected into the blood of each rat (for a normal control group, physiological saline solution was injected) . Then, they were separated and put individually in a box and taped for one hour under an unmanned condition with 8-mm video (SV-K80, Samsung) to observe the results. Only the rats' scratching of the injected area with a rear leg was considered as a scratching behavior.
  • itch-inducing agent 50 ⁇ g of Compound 48/80, Sigma Chemical Corp., USA
  • 100 ⁇ g of histamine Sigma, USA
  • 300 ⁇ g of serotonin Sigma Chemical Corp., USA
  • Inhibition Rate (%) ⁇ l- [absorbance on the area treated with extracts according to the present invention and Compound 48/80 (or histamine) - absorbance on the area not treated with Compound 48/80 (or histamine) ]/ [absorbance on the area treated with Compound 48/80 (or histamine) - absorbance on the area not treated with Compound 48/80 (or histamine)] ⁇ x 100
  • a bag can contain the following components as directed below:
  • a tablet can contain the following components as directed below:
  • a capsule can contain the following components as directed below:
  • 100ml of liquid medicine can contain the following components as directed below:
  • soap containing the below content of each component is prepared.
  • a health beverage can be prepared with the following method.
  • compositional ratios examples of preferable ratios and thus, they could be modified as needed pursuant to local or ethnic preferences.
  • the composition from the present invention contains at least one ginseng extract selected from the group consisting of ginseng or red ginseng extract, its lactic-acid bacteria ferment and its intestinal bacteria ferment, or ginseng saponin derivatives isolated therefrom as effective components, thereby being used as a composition for the prevention or treatment of scratching disease.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention concerne une composition de prévention et de traitement d'une maladie due à une griffure, contenant au moins un extrait de ginseng choisi dans le groupe constitué d'au moins un extrait de ginseng ou de ginseng rouge traité à la vapeur, son ferment bactérien à base d'acide lactique et son ferment bactérien intestinal, ou des dérivés de saponine de ginseng isolés utilisés en tant que principes actifs.
PCT/KR2005/001970 2004-06-29 2005-06-29 Composition contenant de l'extrait de ginseng comprenant des derives de saponine isoles du radix ginseng et ginseng utilise pour empecher et traiter les maladies induites par les griffures WO2006001654A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2004-0049361 2004-06-29
KR1020040049361A KR20060000488A (ko) 2004-06-29 2004-06-29 인삼 또는 홍삼 추출물, 그의 유산균 발효물 및 그의장내세균 발효물로 이루어진 군으로부터 선택된 1종이상의 인삼 추출물 소양증 예방 및 치료제 조성물

Publications (1)

Publication Number Publication Date
WO2006001654A1 true WO2006001654A1 (fr) 2006-01-05

Family

ID=35782030

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2005/001970 WO2006001654A1 (fr) 2004-06-29 2005-06-29 Composition contenant de l'extrait de ginseng comprenant des derives de saponine isoles du radix ginseng et ginseng utilise pour empecher et traiter les maladies induites par les griffures

Country Status (2)

Country Link
KR (1) KR20060000488A (fr)
WO (1) WO2006001654A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090527A2 (fr) * 2006-02-07 2007-08-16 Henkel Ag & Co. Kgaa Agent de traitement capillaire oxydant comprenant un extrait de ginseng
EP2133082A1 (fr) * 2007-03-12 2009-12-16 Institute of Materia, Chinese Academy of Medical Sciences UTILISATION DE GINSENOSIDE Rg1 ET DE SES MÉTABOLITES GINSENOSIDE Rh1 ET PpT
US20120214779A1 (en) * 2006-06-09 2012-08-23 Yongzheng Hui Application of 20(s)-protopanaxadiol in preparation of antidepressants
EP2676671A1 (fr) * 2011-01-21 2013-12-25 Jilin Zixin Pharmaceutical Research Institution LLC Procédé de préparation d'une composition pharmaceutique pour augmenter l'immunité et composition pharmaceutique préparée selon ce procédé
CN107073023A (zh) * 2015-07-16 2017-08-18 智能合成生物中心 血管渗漏综合症的预防或治疗组合物
CN107550961A (zh) * 2017-10-24 2018-01-09 东方红（通化）生物医药股份有限公司 一种应用微生物快速发酵制备人参/西洋参提取物的方法

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101456042B1 (ko) * 2007-01-18 2014-11-03 주식회사 엘지생활건강 노화방지용 화장료 조성물
KR100837213B1 (ko) * 2007-02-05 2008-06-12 주식회사 에이치 엔 비티 산삼배양근의 유효성분인 진세노사이드의 체내흡수율을증진시키는 발효 및 숙성 처리방법
KR101401658B1 (ko) * 2011-06-16 2014-06-02 한국생명공학연구원 진세노사이드 컴파운드 ｋ 또는 이의 유도체로 된 항균제
KR101368634B1 (ko) * 2012-03-28 2014-03-06 영천시(농업기술센터) 산삼배양근 발효물을 유효성분으로 하는 숙취해소 및 면역증진용 건강기능식품 및 이의 제조방법
KR102146706B1 (ko) 2018-10-23 2020-08-24 주식회사한국야쿠르트 비피도박테리움 애니멀리스 서브스페시스 락티스 HY8002와 비피도박테리움 아돌레센티스 HY8502의 유산균 조합을 이용한 진세노사이드 Rd가 강화된 발효홍삼 농축액을 유효성분으로 함유하는 알레르기성 비염을 개선하기 위한 조성물
KR102273108B1 (ko) 2019-11-21 2021-07-06 (주)서울에프엔비 프로바이오틱 활성을 갖는 신규 락토바실러스 플란타럼 kc23 균주 및 참당귀 추출물을 이용한 발효조성물

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR840000561B1 (ko) * 1982-11-02 1984-04-23 원본미기재 인삼의 지상부 추출물을 안정화시켜 첨가한 샴푸 및 린스 조성물
JPH11236329A (ja) * 1997-12-18 1999-08-31 Meiji Milk Prod Co Ltd 浴剤組成物
US6432455B2 (en) * 1998-07-10 2002-08-13 Vit Immune, L.L.C. Symptomatic relief of allergic reactions
JP2003238424A (ja) * 2002-01-30 2003-08-27 Iruha:Kk 生物転換人参組成物およびその製造方法
US6630176B2 (en) * 2000-03-07 2003-10-07 Mount Sinai School Of Medicine Of New York University Herbal remedies for treating allergies and asthma
WO2004050892A1 (fr) * 2002-12-05 2004-06-17 Hongrim Trading Co., Ltd. Ginseng fermente par une bacterie d'acide lactique, yogourt la contenant et bacterie d'acide lactique utilisee pour la preparation d'un yogourt

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR840000561B1 (ko) * 1982-11-02 1984-04-23 원본미기재 인삼의 지상부 추출물을 안정화시켜 첨가한 샴푸 및 린스 조성물
JPH11236329A (ja) * 1997-12-18 1999-08-31 Meiji Milk Prod Co Ltd 浴剤組成物
US6432455B2 (en) * 1998-07-10 2002-08-13 Vit Immune, L.L.C. Symptomatic relief of allergic reactions
US6630176B2 (en) * 2000-03-07 2003-10-07 Mount Sinai School Of Medicine Of New York University Herbal remedies for treating allergies and asthma
JP2003238424A (ja) * 2002-01-30 2003-08-27 Iruha:Kk 生物転換人参組成物およびその製造方法
WO2004050892A1 (fr) * 2002-12-05 2004-06-17 Hongrim Trading Co., Ltd. Ginseng fermente par une bacterie d'acide lactique, yogourt la contenant et bacterie d'acide lactique utilisee pour la preparation d'un yogourt

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HASEGAWA H. ET AL: "Main ginseng saponin metabolites formed by intestinal bacteria", PLANTA MED., vol. 62, no. 5, 1996, pages 453 - 457 *
TOHDA C. ET AL: "Inhibitory effect of Byakko-ka-ninjin-to on itch in a mouse model of atopic dermatitis", PHYTOTHER. RES., vol. 14, no. 3, 2000, pages 192 - 194 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007090527A2 (fr) * 2006-02-07 2007-08-16 Henkel Ag & Co. Kgaa Agent de traitement capillaire oxydant comprenant un extrait de ginseng
WO2007090527A3 (fr) * 2006-02-07 2007-10-11 Henkel Kgaa Agent de traitement capillaire oxydant comprenant un extrait de ginseng
US20120214779A1 (en) * 2006-06-09 2012-08-23 Yongzheng Hui Application of 20(s)-protopanaxadiol in preparation of antidepressants
EP2133082A1 (fr) * 2007-03-12 2009-12-16 Institute of Materia, Chinese Academy of Medical Sciences UTILISATION DE GINSENOSIDE Rg1 ET DE SES MÉTABOLITES GINSENOSIDE Rh1 ET PpT
EP2133082A4 (fr) * 2007-03-12 2010-03-24 Inst Materia Medica Cams UTILISATION DE GINSENOSIDE Rg1 ET/OU DE SES MÉTABOLITES GINSENOSIDE Rh1 ET PpT
US8765695B2 (en) 2007-03-12 2014-07-01 Jecui Health Industry Corp. Ltd. Use of ginsenoside RG1, its metabolites ginsenoside RH1 and/or PPT
EP2676671A1 (fr) * 2011-01-21 2013-12-25 Jilin Zixin Pharmaceutical Research Institution LLC Procédé de préparation d'une composition pharmaceutique pour augmenter l'immunité et composition pharmaceutique préparée selon ce procédé
EP2676671A4 (fr) * 2011-01-21 2014-07-16 Jilin Zixin Pharmaceutical Res Institution Llc Procédé de préparation d'une composition pharmaceutique pour augmenter l'immunité et composition pharmaceutique préparée selon ce procédé
CN107073023A (zh) * 2015-07-16 2017-08-18 智能合成生物中心 血管渗漏综合症的预防或治疗组合物
EP3181138A4 (fr) * 2015-07-16 2018-03-14 Intelligent Synthetic Biology Center Composition pour la prévention ou le traitement du syndrome de fuite vasculaire
US10391110B2 (en) 2015-07-16 2019-08-27 Intelligent Synthetic Biology Center Composition for preventing or treating vascular leak syndrome
CN107550961A (zh) * 2017-10-24 2018-01-09 东方红（通化）生物医药股份有限公司 一种应用微生物快速发酵制备人参/西洋参提取物的方法

Also Published As

Publication number Publication date
KR20060000488A (ko) 2006-01-06

Similar Documents

Publication Publication Date Title
WO2006001654A1 (fr) Composition contenant de l'extrait de ginseng comprenant des derives de saponine isoles du radix ginseng et ginseng utilise pour empecher et traiter les maladies induites par les griffures
RU2294208C2 (ru) Применение экстракта обработанного женьшеня и выделенных из него сапонинов
CN104623670A (zh) 一种含西红花素的组合物及其应用
CN105358168B (zh) 具有用于缓解经前期综合征及痛经的功能的组合物
US7371416B2 (en) Method for preparing processed ginseng to obtain increased amount of ginsenoside RG5
CN105942498A (zh) 具有治疗糖尿病作用的功能性营养食品组合及其制备方法
US20180296615A1 (en) Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient
KR100555652B1 (ko) 약효가 증강된 파낙스속 식물의 가공 추출물, 그 제조방법및 그를 함유하는 암 및 알러지 질환의 예방 및 치료를위한 조성물
KR100688425B1 (ko) 유효 성분으로 진세노시드 Ｒｈ2를 함유하는 뇌세포 보호조성물
KR100759772B1 (ko) 유효 성분으로 진세노시드 Ｒｈ2를 함유하는 뇌세포 보호조성물
KR20110093477A (ko) 발효 홍삼을 포함하는 항암 조성물
KR20200089782A (ko) 생강, 병풀 및 모시잎 추출물의 혼합물을 유효성분으로 포함하는 비알콜성 지방간 질환의 예방 또는 개선용 조성물
KR100533505B1 (ko) 인삼으로부터 분리된 사포닌 유도체를 함유하는 알레르기질환의 예방 및 치료를 위한 건강보조식품
KR101671571B1 (ko) 당 흡수 저해용 인삼 씨 조성물 및 이것의 제조방법
KR102250906B1 (ko) 진세노사이드 mc1을 포함하는 염증성 질환 예방 또는 치료용 조성물
KR100456417B1 (ko) 약효가 증가된 특수가공처리 인삼 추출물을 함유하는뇌졸증의 예방 및 치료를 위한 조성물
KR100551564B1 (ko) 인삼으로부터 분리된 사포닌 유도체를 함유하는 알레르기질환의 예방 및 치료를 위한 조성물
JP2005145897A (ja) サポニン吸収促進組成物
CN114098072A (zh) 一种辅助调理血糖的药食同源药材食材组合物、提取物及其制备方法与应用
KR20200038113A (ko) 갈화 발효 추출물을 포함하는 갱년기 증상의 예방 또는 치료용 조성물
KR20170087064A (ko) 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase